Blau Farmacêutica, Bergamo tell Brazil CADE merger won't affect supply of chemotherapy drugs
Brazil-based pharmaceutical company Blau Farmacêutica has told the national competition authority that its planned acquisition of rival Bergamo won’t affect the market supply of chemotherapy drugs cisplatin and carboplatin. The parties...To view the full article, register now.
Already a subscriber? Click here to view full article